Barclays Issues Pessimistic Forecast for Organon & Co. (NYSE:OGN) Stock Price

Organon & Co. (NYSE:OGN - Free Report) had its target price cut by Barclays from $26.00 to $24.00 in a research note released on Friday,Benzinga reports. They currently have an overweight rating on the stock.

Several other research firms also recently issued reports on OGN. Morgan Stanley cut their price objective on shares of Organon & Co. from $17.00 to $16.00 and set an "equal weight" rating on the stock in a report on Friday. TD Cowen raised shares of Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $20.80.

Organon & Co. Trading Up 1.1 %

OGN traded up $0.18 during trading on Friday, hitting $15.46. 3,414,065 shares of the stock were exchanged, compared to its average volume of 2,844,831. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The firm has a 50 day simple moving average of $15.36 and a 200 day simple moving average of $17.34. The firm has a market cap of $3.98 billion, a price-to-earnings ratio of 3.07, a P/E/G ratio of 0.83 and a beta of 0.76. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10.

Organon & Co. (NYSE:OGN - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. As a group, equities analysts expect that Organon & Co. will post 3.82 EPS for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.25%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.'s dividend payout ratio (DPR) is 22.22%.

Institutional Investors Weigh In On Organon & Co.

Large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Organon & Co. by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company's stock worth $453,593,000 after buying an additional 218,165 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company's stock worth $166,391,000 after acquiring an additional 11,140,388 shares during the period. Massachusetts Financial Services Co. MA increased its stake in shares of Organon & Co. by 1.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company's stock worth $147,634,000 after acquiring an additional 136,760 shares during the period. LSV Asset Management raised its holdings in shares of Organon & Co. by 0.4% during the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company's stock worth $112,274,000 after purchasing an additional 30,557 shares during the last quarter. Finally, Deprince Race & Zollo Inc. raised its holdings in shares of Organon & Co. by 7.0% during the fourth quarter. Deprince Race & Zollo Inc. now owns 4,729,258 shares of the company's stock worth $70,561,000 after purchasing an additional 308,267 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.